Shair Group Begins Research Collaboration with Merck

Exciting results in the Shair lab promise both insights into the genetic control of acute myeloid leukemia and a potential treatment. The Shair group’s preclinical work, which had been supported by the Blavatnik Biomedical Accelerator, will now become a collaboration with Merck.